All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Mosunetuzumab for the treatment of high-risk, heavily pretreated R/R follicular lymphoma
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
|
A subgroup analysis from the pivotal phase II GO29781 (NCT02500407) study of mosunetuzumab was presented at the EHA 2024 Congress by Sarit Assouline.1 This analysis primarily focused on outcomes among patients with high-risk, heavily pretreated R/R FL with ≥3 years of follow-up. Subgroups included patients with a history of POD24, patients receiving mosunetuzumab in the 3L vs 4L or later, and patients aged ≥65 years.1 |
| Key learnings: |
|
In the subgroup analysis, ORR rates were 78%, 74%, and 81% in the overall, non-POD24, and POD24 populations, respectively. |
|
Rates of CR did not differ significantly across the subgroups, with the highest CR rate (68.6%) observed in patients treated with mosunetuzumab in the 3L (compared with 54.5% in patients treated in the 4L or later). |
|
The 3-year PFS rate did not differ significantly between groups and was 43%, 44%, and 42% for the overall, non-POD24, and POD24 populations, respectively. |
|
The 3-year OS rates were also similar across subgroups (83%, 81%, and 84% for the overall, non-POD24, and POD24 populations, respectively). |
|
The safety profile for each subgroup, including in older patients aged ≥65 years, was largely consistent with that for the overall population. |
|
Overall, fixed-duration mosunetuzumab resulted in consistently favorable outcomes across subgroups of patients with high-risk R/R FL, including those with POD24, and in older patients. Efficacy outcomes may be improved with mosunetuzumab use in earlier rather than later lines of treatment. |
Abbreviations: 3L, third-line; 4L, fourth-line; EHA, European Hematology Association; CR, complete response; FL, follicular lymphoma; OS, overall survival; PFS, progression-free survival; POD24, progression of disease within 24 months from the start of first-line therapy; R/R, relapsed/refractory.
- Assouline S. Mosunetuzumab demonstrates clinically meaningful outcomes in high-risk patients with heavily pre-treated R/R FL after ≥3 years of follow-up: Subgroup analysis of a pivotal phase II study. Oral abstract #233. European Hematology Association (EHA) 2024 Congress; Jun 13-17; Madrid, ES.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
14 votes - 25 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox